Wolverine Trading, LLC Intellia Therapeutics, Inc. Put Options Transaction History

Wolverine Trading, LLC

15 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$19.72 - $27.36 $124,236 - $172,368	6,300 Added 27.51%	29,200 $600,000
Q2 2024 Aug 14, 2024	BUY	$20.02 - $27.22 $34,034 - $46,274	1,700 Added 8.02%	22,900 $512,000
Q1 2024 May 15, 2024	BUY	$23.82 - $32.8 $14,292 - $19,680	600 Added 2.91%	21,200 $583,000
Q4 2023 Feb 14, 2024	SELL	$23.16 - $32.34 $78,744 - $109,956	-3,400 Reduced 14.17%	20,600 $628,000
Q3 2023 Nov 15, 2023	SELL	$31.62 - $45.78 $79,050 - $114,450	-2,500 Reduced 9.43%	24,000 $758,000
Q2 2023 Aug 23, 2023	BUY	$34.58 - $46.03 $76,076 - $101,266	2,200 Added 9.05%	26,500 $1.08 Million
Q1 2023 May 15, 2023	SELL	$33.3 - $44.82 $486,179 - $654,372	-14,600 Reduced 37.53%	24,300 $875,000
Q4 2022 Feb 14, 2023	SELL	$33.21 - $62.69 $112,914 - $213,146	-3,400 Reduced 8.04%	38,900 $1.36 Million
Q3 2022 Nov 14, 2022	BUY	$53.92 - $71.7 $113,232 - $150,570	2,100 Added 5.22%	42,300 $2.34 Million
Q2 2022 Aug 15, 2022	BUY	$38.49 - $76.21 $1.2 Million - $2.38 Million	31,200 Added 346.67%	40,200 $2.11 Million
Q1 2022 May 16, 2022	BUY	$58.27 - $118.99 $122,367 - $249,879	2,100 Added 30.43%	9,000 $650,000
Q4 2021 Feb 14, 2022	SELL	$100.76 - $138.36 $987,448 - $1.36 Million	-9,800 Reduced 58.68%	6,900 $837,000
Q3 2021 Nov 12, 2021	SELL	$132.37 - $176.78 $569,191 - $760,154	-4,300 Reduced 20.48%	16,700 $2.3 Million
Q2 2021 Aug 06, 2021	BUY	$60.88 - $161.91 $334,840 - $890,505	5,500 Added 35.48%	21,000 $3.18 Million
Q1 2021 May 14, 2021	BUY	$46.59 - $83.68 $722,145 - $1.3 Million	15,500 New	15,500 $1.12 Million

313

91.5M

442K

880K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $1.09B
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Wolverine Trading, LLC with notifications on news.